Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology-Basic: Radiopharmaceutical Therapy

Anti-Cadherin 3 antibody labeled with Y-90 effectively inhibits tumor growth of non-small cell lung cancer xenograft in nude mice by radioimmunotherapy

Hirokazu Satoh, Fumiko Nomura, Youichi Aikawa, Romi Kotaka, Masahiko Watanabe, Yasutaka Saito, Akio Nagano, Akihiro Hino, Tadashi Matsuura and Yukio Sudo
Journal of Nuclear Medicine May 2010, 51 (supplement 2) 1151;
Hirokazu Satoh
1Research & Development, Perseus Proteomics Inc., Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fumiko Nomura
1Research & Development, Perseus Proteomics Inc., Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Youichi Aikawa
1Research & Development, Perseus Proteomics Inc., Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Romi Kotaka
1Research & Development, Perseus Proteomics Inc., Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masahiko Watanabe
2Research Dept., FUJIFILM RI Pharma Co., Ltd., Sammu, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasutaka Saito
2Research Dept., FUJIFILM RI Pharma Co., Ltd., Sammu, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akio Nagano
2Research Dept., FUJIFILM RI Pharma Co., Ltd., Sammu, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akihiro Hino
2Research Dept., FUJIFILM RI Pharma Co., Ltd., Sammu, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tadashi Matsuura
1Research & Development, Perseus Proteomics Inc., Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yukio Sudo
1Research & Development, Perseus Proteomics Inc., Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 51 no. supplement 2 1151

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online November 3, 2014.

Copyright & Usage 
© 2010

Author Information

  1. Hirokazu Satoh1,
  2. Fumiko Nomura1,
  3. Youichi Aikawa1,
  4. Romi Kotaka1,
  5. Masahiko Watanabe2,
  6. Yasutaka Saito2,
  7. Akio Nagano2,
  8. Akihiro Hino2,
  9. Tadashi Matsuura1 and
  10. Yukio Sudo1
  1. 1Research & Development, Perseus Proteomics Inc., Tokyo, Japan
  2. 2Research Dept., FUJIFILM RI Pharma Co., Ltd., Sammu, Japan

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: November 2014 to April 2025

AbstractFullPdf
Nov 2014100
Jan 2015300
May 2015300
Jun 2015500
Jul 2015200
Aug 2015200
Sep 2015200
Dec 2015100
Jan 2016100
Mar 2016200
Apr 2016500
May 2016100
Jun 2016600
Jul 2016300
Aug 20161200
Sep 2016100
Oct 2016600
Nov 2016300
Dec 2016300
Jan 2017600
Feb 2017200
Mar 2017200
Apr 2017300
May 2017300
Jun 2017300
Aug 2017600
Sep 2017400
Oct 2017200
Nov 2017500
Dec 2017200
Jan 2018100
Feb 2018200
Mar 20182600
Apr 2018100
May 2018300
Jun 2018200
Jul 2018100
Aug 2018200
Sep 2018300
Oct 2018400
Nov 20181000
Dec 20181900
Jan 20191400
Feb 20191300
Mar 20191200
Apr 2019600
May 2019300
Jun 2019400
Jul 2019600
Aug 20191500
Sep 2019500
Oct 2019600
Nov 20191300
Dec 20191000
Jan 2020900
Feb 2020800
Mar 20201500
Apr 2020900
May 2020200
Jun 2020400
Jul 2020600
Aug 20208100
Sep 202013500
Oct 20202200
Nov 20202700
Dec 2020800
Jan 2021900
Feb 20211200
Mar 2021700
Apr 20211700
May 20211000
Jun 2021800
Jul 20212500
Aug 20215800
Sep 20211700
Oct 20212200
Nov 20218700
Dec 20214200
Jan 20227400
Feb 20222600
Mar 20222900
Apr 20221300
May 20222700
Jun 2022300
Jul 2022200
Aug 2022600
Sep 2022200
Oct 2022200
Nov 2022100
Dec 2022400
Jan 2023300
Feb 2023300
Mar 2023800
Apr 2023300
May 2023700
Jun 2023500
Jul 2023600
Aug 20231000
Sep 20231000
Oct 20231200
Nov 2023100
Dec 2023500
Jan 2024400
Feb 2024300
Mar 2024400
Apr 2024200
May 20241100
Jun 2024800
Jul 2024500
Aug 20241200
Sep 2024500
Oct 2024300
Nov 2024600
Dec 2024600
Jan 2025400
Feb 2025800
Mar 2025600
Apr 20251300
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 51, Issue supplement 2
May 2010
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Anti-Cadherin 3 antibody labeled with Y-90 effectively inhibits tumor growth of non-small cell lung cancer xenograft in nude mice by radioimmunotherapy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Anti-Cadherin 3 antibody labeled with Y-90 effectively inhibits tumor growth of non-small cell lung cancer xenograft in nude mice by radioimmunotherapy
Hirokazu Satoh, Fumiko Nomura, Youichi Aikawa, Romi Kotaka, Masahiko Watanabe, Yasutaka Saito, Akio Nagano, Akihiro Hino, Tadashi Matsuura, Yukio Sudo
Journal of Nuclear Medicine May 2010, 51 (supplement 2) 1151;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Anti-Cadherin 3 antibody labeled with Y-90 effectively inhibits tumor growth of non-small cell lung cancer xenograft in nude mice by radioimmunotherapy
Hirokazu Satoh, Fumiko Nomura, Youichi Aikawa, Romi Kotaka, Masahiko Watanabe, Yasutaka Saito, Akio Nagano, Akihiro Hino, Tadashi Matsuura, Yukio Sudo
Journal of Nuclear Medicine May 2010, 51 (supplement 2) 1151;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology-Basic: Radiopharmaceutical Therapy

  • Iodide-131 humanized monoclonal antibody to CD 25 in relapsed Hodgkin’s lymphoma - First results in compassionate use
  • Peptide receptor radionuclide therapy (PRRT) of treatment-refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 labeled somatostatin analogs: Toxicity, response and survival analysis
  • Treatment of unoperable and chemorefractory primary and secondary liver malignancies with Yttrium-90 resin microspheres
Show more Oncology-Basic: Radiopharmaceutical Therapy

Oncology: Radiopharmaceutical Therapy Posters

  • During repeated Sm-153-EDTMP therapy a temporary decrease in peripheral platelet count is balanced by an increased platelet function per cell
  • 177Lu-BPAMD - From bone imaging to therapy with a macrocycle-bisphosphonate ligand
  • Long-term evaluation of renal toxicity with multiple doses of high activity 111-In-pentetreotide in patients with disseminated neuroendocrine tumors
Show more Oncology: Radiopharmaceutical Therapy Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire